Westinghouse Signs Memorandum of Understanding with NorthStar to Produce Medical Radioisotopes
Westinghouse Electric Company and NorthStar Medical Radioisotopes today announced a Memorandum of Understanding to explore producing medical radioisotopes from the core of commercial nuclear reactors, and methods of global distribution. The exploration involves generating the most widely used radioisotope in medical diagnostic imaging by treating an isotope of the chemical element molybdenum rather than enriched uranium.
“Together, the companies can have a significant impact on the global supply of this essential diagnostic isotope,” said Cindy Pezze, vice president and chief technology officer, Westinghouse.
The effort is to address a global production capacity shortage of the medical radioisotope molybdenum-99 (Mo-99), as well as a nuclear proliferation concern with current methods, which rely on enriched uranium as source material. Both societal needs will be answered by using the highly reliable, high-volume production capacity of commercial nuclear reactors to make Mo-99 by irradiating molybdenum-98, and would require little capital investment by nuclear plant operators.
“Nuclear plants operate at very high capacity factors, and there are plants around the world that have the capability to produce Mo-99,” Pezze said. “Not only does commercial nuclear power provide reliable electricity without greenhouse gases, it can additionally contribute to society by making important diagnostic isotopes available globally.”
Westinghouse has a patent pending for producing medical radioisotopes using the existing Westinghouse plant design Incore Instrumentation System. NorthStar has been developing a process for using enriched Mo-98 targets as the starting point for Mo-99 rather than enriched uranium.
Jim Harvey, chief science officer, NorthStar, stated, “This is a tremendous opportunity to further address the chronic shortage of medical isotopes. While we will continue developing alternative processes for Mo-99 production already underway, working with Westinghouse and commercial nuclear reactors will be a game changer, providing NorthStar with considerable medical radioisotope production redundancy and outage reserve capacity, both of which are critical.”
Westinghouse Electric Company, a group company of Toshiba Corporation (TKY:6502), is the world's pioneering nuclear energy company and is a leading supplier of nuclear plant products and technologies to utilities throughout the world. The Westinghouse nuclear business supplied the world's first pressurized water reactor in 1957 in Shippingport, Pa., U.S. Today, Westinghouse technology is the basis for approximately one-half of the world's operating nuclear plants.
Based in Madison, Wis., NorthStar Medical Radioisotopes LLC was founded in 2006 to address the needs of the nuclear medicine market in the United States. A wholly owned subsidiary of NorthStar Medical Technologies LLC, the company is committed to resolving industry-wide supply challenges that have caused shortages of vital medical isotopes, negatively impacting patient care and stalling clinical research. Its patented technologies include innovative non-uranium based molybdenum-99 production methods, a novel separation chemistry system and tools for the nuclear medicine market.
Westinghouse Electric Company LLC
+1 412-374-6379 (office) +1 412-992-1947 (mobile)
Public Relations Manager
Westinghouse Americas Region
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
JustPremium Launches Rich Video Product Suite19.3.2018 08:00 | Pressemelding
Programmatic rich media and video ad marketplace, JustPremium, has today announced the launch of a new product suite, Rich Video. The new offering allows clients to build multiple rich video ad units with a single click using the advertisers existing assets. Using Rich Video allows advertisers to create an engaging advert, leading to higher engagement and interaction rates. Ultimately these formats help create a better user experience and a higher return on investment. JustPremium launches this product at a time when quality video inventory has never been more in demand, and brand-safe video inventory that advertisers require has never been in shorter supply. Rich Video allows publishers to build multiple creative ad units in minutes, enabling them to test different options and optimise their message to give the best performance. By utilising the assets that have already been created for Facebook, Adwords and YouTube, this process allows advertisers to supercharge their existing conten
GovSat-1 Satellite Goes Operational19.3.2018 07:40 | Pressemelding
GovSat-1 enters operational service today, to provide secure communications to governmental and institutional users. GovSat-1 is the first satellite of GovSat, a public private partnership between the Government of Luxembourg and the world-leading satellite operator SES. The satellite was launched into space on 31 January on board a flight-proven SpaceX Falcon 9 rocket from Cape Canaveral Air Force Station, and has since undergone extensive testing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180319005458/en/ GovSat-1 launch. (Photo: SpaceX) The multi-mission satellite is operated by GovSat from the Secure Mission Operations Centre in Luxembourg. The highly flexible and resilient GovSat-1 payload uses dedicated frequencies in X-band and military Ka-band. It enables an array of applications such as connectivity for theatres of operation, interconnection of institutional or defence sites, border control, Intelligence, Surve
Digi Communications N.V.: Announcement on the Convocation Date for the Company’s GSM Approving the 2017 Annual Report19.3.2018 07:34 | Pressemelding
The Company would like to inform its investors and the market that the Board of Directors anticipates that on Wednesday, 21 March 2018, it will convene the general shareholders meeting (the “GSM”) called to approve, among others, the 2017 Annual Report. On the same date, the Company will make public, among others, its 2017 Annual Report and the auditor’s report. In accordance with the provisions of the articles of association of the Company, the GSM is scheduled to take place on 2 May 2018. Therefore, we would like to inform you with respect to the update to the Company’s Financial Reporting Calendar for 2018, which is available on Digi’s website. For details, please access the Digi’s website: www.digi-communications.ro (Investor Relations Section). About Digi Communications NV Digi is the parent holding company of RCS & RDS, a leading provider of pay TV and telecommunications services in Romania and Hungary. In addition, RCS & RDS provides mobile services as an MVNO to the large Roman
Dai Nippon Printing Chooses Gemalto’s Biometric Facial Recognition Solution to Facilitate Mobile Banking Access in Japan19.3.2018 06:00 | Pressemelding
Gemalto, the world leader in digital security, today announced that it has been selected by Dai Nippon Printing (DNP), a financial solutions provider in Japan, to make mobile banking transactions easier to use. Leveraging Gemalto’s facial biometric authentication solution - Mobile Protector- DNP has started to offer facial recognition to secure access to its mobile banking apps. This enables banking customers to easily and quickly log on to mobile banking services upon successful facial authentication, providing a more convenient user experience. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180318005005/en/ Facial recognition for mobile banking authentication. (Photo: Gemalto) Gemalto’s 2017 eBanking Trends research found that 68 percent of banks plan to implement facial recognition over the next five years. 80 percent of surveyed consumers perceived biometrics to be more secure than the traditional username and password co
Gemalto Helps European Banks Build Business Opportunities from PSD219.3.2018 06:00 | Pressemelding
Gemalto, the world leader in digital security, believes that the implementation of PSD2 (Payment Services Directive 2) offers European banks a unique opportunity to deliver digital innovation, robust protection and seamless user experience that will be critical in a new era of open markets. The Regulatory Technical Standards (RTS) have just been published in the EU Official Journal, and detail the responsibilities and obligations of all banking and payment stakeholders concerning access to account, customer data protection, user convenience, and payment security. Gemalto believes that long term success will be built around solutions tailored to individual requirements, whilst drawing on products and services already proven to deliver the core principles of PSD2. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180318005025/en/ Solutions to help financial institutions for implementation of PSD2. Credit: istockphoto Adoption of t
ExThera Medical Announces Creation of European Subsidiary19.3.2018 05:23 | Pressemelding
ExThera Medical Corporation, a developer of therapies for removing bacteria and viruses from blood, today announced the company’s plan to create ExThera Medical Europe and appointed Carla Kikken-Jussen as managing director of the new wholly-owned subsidiary. Carla brings more than 30 years of experience in clinical research and the commercialization of new medical devices in the European market to ExThera Medical, where she will oversee the strategic direction for ExThera’s European operations. “The establishment of our European subsidiary is an exciting milestone as we prepare for commercialization,” said Robert Ward, President and CEO of ExThera Medical. “Carla has a distinguished track record in medical device development and commercialization, including overseeing clinical research, regulatory affairs, quality assurance, and operations. As CEO of her company, Meditech, she successfully supported the rapid clinical adoption of many new medical devices. Carla’s strategic leadership w